Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 110-118

  Germani, Aldo ^a   Matrone, Antonio ^a   Grossi, Valentina ^b   Peserico, Alessia ^a   Sanese, Paola ^a   Liuzzi, Micaela ^c   Palermo, Rocco ^d   Murzilli, Stefania ^e   Campese, Antonio Francesco ^d   Ingravallo, Giuseppe ^c   Canettieri, Gianluca ^d   Tezil, Tugsan ^a   Simone, Cristiano ^a,c  

^a Laboratory of Signal dependent Transcription   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^e DIMO University of Bari ^*  (Italy)

Author keywords

Cell death; Chemoresistance; Colorectal cancer; Dual therapy; P38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BIM PROTEIN; CISPLATIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN P21; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIM GENE; CANCER CELL; CANCER RESISTANCE; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GADD45 GENE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; P21 GENE; PRIORITY JOURNAL; PTEN GENE; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION;

CELL DEATH; CHEMORESISTANCE; COLORECTAL CANCER; DUAL THERAPY; P38 MAPK;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; HT29 CELLS; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR TARGETED THERAPY; REAL-TIME POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893131728     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.035     Document Type: Article

References (39)

1. Benson V.S., Patnick J., Davies A.K., Nadel M.R., Smith R.A., Atkin W.S., International N. Colorectal Cancer Screening, Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. International Journal of cancer. Journal International du Cancer 2008, 122:1357-1367.
2. Ozols R.F. Ovarian cancer: new clinical approaches. Cancer Treatment Reviews 1991, 18(Suppl A):77-83.
3. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews 2007, 33:9-23.
4. Marin J.J., Sanchez de Medina F., Castano B., Bujanda L., Romero M.R., Martinez-Augustin O., Moral-Avila R.D., Briz O. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews 2012, 44:148-172.
5. Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., Harrap K.R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Research 1992, 52:3857-3864.
6. Nakayama K., Kanzaki A., Ogawa K., Miyazaki K., Neamati N., Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP, International journal of cancer. Journal International du Cancer 2002, 101:488-495.
7. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:14298-14302.
8. Du X., Wang X., Li H., Sun H., Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1) Metallomics: Integrated Biometal Science 2012, 4:679-685.
9. Katano K., Kondo A., Safaei R., Holzer A., Samimi G., Mishima M., Kuo Y.M., Rochdi M., Howell S.B. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research 2002, 62:6559-6565.
10. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical Pharmacology 2000, 60:1305-1313.
11. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews: MMBR 2004, 68:320-344.
12. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson J.K., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
13. Brozovic A., Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Letters 2007, 251:1-16.
14. Gout S., Morin C., Houle F., Huot J. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Research 2006, 66:9117-9124.
15. Suarez-Cuervo C., Merrell M.A., Watson L., Harris K.W., Rosenthal E.L., Vaananen H.K., Selander K.S. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clinical & Experimental Metastasis 2004, 21:525-533.
16. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. P38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. Journal of Cell Science 2002, 115:3193-3206.
17. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. The Biochemical Journal 2010, 429:403-417.
18. Comes F., Matrone A., Lastella P., Nico B., Susca F.C., Bagnulo R., Ingravallo G., Modica S., Lo Sasso G., Moschetta A., Guanti G., Simone C., sdsdsdsdsdsd Cell Death and Differentiation 2007, 14:693-702.
19. Simone C. Signal-dependent control of autophagy and cell death in colorectal cancer cell: the role of the p38 pathway. Autophagy 2007, 3:468-471.
20. Paillas S., Boissiere F., Bibeau F., Denouel A., Mollevi C., Causse A., Denis V., Vezzio-Vie N., Marzi L., Cortijo C., Ait-Arsa I., Askari N., Pourquier P., Martineau P., Del Rio M., Gongora C. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Research 2011, 71:1041-1049.
21. Paillas S., Causse A., Marzi L., de Medina P., Poirot M., Denis V., Vezzio-Vie N., Espert L., Arzouk H., Coquelle A., Martineau P., Del Rio M., Pattingre S., Gongora C. MAPK14/p38alpha confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy 2012, 8:1098-1112.
22. Yang S.Y., Miah A., Sales K.M., Fuller B., Seifalian A.M., Winslet M. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. International Journal of Oncology 2011, 38:1695-1702.
23. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
24. Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK, vol. 406, 2011, p. 299-304.
25. Guo X., Ma N., Wang J., Song J., Bu X., Cheng Y., Sun K., Xiong H., Jiang G., Zhang B., Wu M., Wei L. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008, 8:375.
26. Chung L.Y., Tang S.J., Sun G.H., Chou T.Y., Yeh T.S., Yu S.L., Sun K.H. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clinical Cancer Research: An Official Journal of the american Association for Cancer Research 2012, 18:4037-4047.
27. Chiacchiera F., Matrone A., Ferrari E., Ingravallo G., Lo Sasso G., Murzilli S., Petruzzelli M., Salvatore L., Moschetta A., Simone C., p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription Cell Death and Differentiation 2009, 16:1203-1214.
28. Marengo B., De Ciucis C.G., Ricciarelli R., Furfaro A.L., Colla R., Canepa E., Traverso N., Marinari U.M., Pronzato M.A., Domenicotti C. P38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment. Cell Death & Disease 2013, 4:e589.
29. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
30. Matrone A., Grossi V., Chiacchiera F., Fina E., Cappellari M., Caringella A.M., Di Naro E., Loverro G., Simone C. P38alpha is required for ovarian cancer cell metabolism and survival. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 2010, 20:203-211.
31. Daitoku H., Sakamaki J., Fukamizu A. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochimica et Biophysica Acta 1813, 2011:1954-1960.
32. Chiacchiera F., Grossi V., Cappellari M., Peserico A., Simonatto M., Germani A., Russo S., Moyer M.P., Resta N., Murzilli S., Simone C. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Letters 2012, 324:98-108.
33. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27:2276-2288.
34. Chiacchiera F., Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010, 9:1091-1096.
35. Chiacchiera F., Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Letters 2008, 265:16-26.
36. Chiacchiera F., Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 2009, 5:1030-1033.
37. Grossi V., Liuzzi M., Murzilli S., Martelli N., Napoli A., Ingravallo G., Del Rio A., Simone C. Sorafenib inhibits p38alpha activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biology & Therapy 2012, 13:1471-1481.
38. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
39. Fernandez de Mattos S., Villalonga P., Clardy J., Lam E.W. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Molecular cancer therapeutics 2008, 7:3237-3246.